AbbVie Inc. Equity Securities without Readily Determinable Fair Value, Amount
AbbVie Inc. (ABBV) had Equity Securities without Readily Determinable Fair Value, Amount of $162.00 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount · last filed 2026-08-03
- 2026-06-30: Equity Securities without Readily Determinable Fair Value, Amount $162.00M.
- 2026-03-31: Equity Securities without Readily Determinable Fair Value, Amount $163.00M.
- 2025-12-31: Equity Securities without Readily Determinable Fair Value, Amount $159.00M.
- 2025-09-30: Equity Securities without Readily Determinable Fair Value, Amount $172.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Amount |
|---|---|
| 2026-06-30 | $162.00M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $163.00M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $159.00M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $172.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $166.00M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $157.00M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $169.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $153.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $160.00M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $161.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $159.00M 10-K · filed 2025-02-14 |
| 2023-09-30 | $131.00M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $124.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $115.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $129.00M 10-K · filed 2024-02-20 |
| 2022-09-30 | $143.00M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $148.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $147.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $149.00M 10-K · filed 2023-02-17 |
| 2021-09-30 | $132.00M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $118.00M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $110.00M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $102.00M 10-K · filed 2022-02-18 |
| 2020-09-30 | $96.00M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $91.00M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $75.00M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $66.00M 10-K · filed 2021-02-19 |
| 2019-09-30 | $67.00M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $65.00M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $77.00M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $84.00M 10-K · filed 2020-02-21 |
| 2018-09-30 | $78.00M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |